Elevance Health (ELV) Expected to Announce Quarterly Earnings on Tuesday

Elevance Health (NYSE:ELV - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, April 22nd. Analysts expect Elevance Health to post earnings of $10.60 per share and revenue of $46.26 billion for the quarter. Elevance Health has set its FY 2025 guidance at 34.150-34.850 EPS.Individual interested in listening to the company's earnings conference call can do so using this link.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. On average, analysts expect Elevance Health to post $34 EPS for the current fiscal year and $39 EPS for the next fiscal year.

Elevance Health Price Performance

Shares of ELV stock traded down $10.60 during trading hours on Friday, hitting $424.44. 3,569,359 shares of the company's stock were exchanged, compared to its average volume of 1,450,101. The firm has a 50 day moving average of $416.11 and a two-hundred day moving average of $411.67. Elevance Health has a fifty-two week low of $362.21 and a fifty-two week high of $567.26. The firm has a market cap of $96.09 billion, a P/E ratio of 16.57, a P/E/G ratio of 1.18 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 0.71.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th were given a $1.71 dividend. This is a positive change from Elevance Health's previous quarterly dividend of $1.63. The ex-dividend date of this dividend was Monday, March 10th. This represents a $6.84 annualized dividend and a dividend yield of 1.61%. Elevance Health's dividend payout ratio (DPR) is 26.71%.

Insider Activity at Elevance Health

In related news, CAO Ronald W. Penczek sold 443 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $415.13, for a total value of $183,902.59. Following the sale, the chief accounting officer now owns 1,847 shares of the company's stock, valued at $766,745.11. This trade represents a 19.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the transaction, the executive vice president now owns 10,116 shares of the company's stock, valued at $4,008,970.80. This trade represents a 25.73 % decrease in their position. The disclosure for this sale can be found here. 0.29% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on ELV. Argus upgraded Elevance Health from a "hold" rating to a "buy" rating and set a $450.00 price objective for the company in a research note on Monday, March 17th. Stephens downgraded Elevance Health from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $520.00 to $440.00 in a research note on Wednesday, January 22nd. Barclays lifted their target price on shares of Elevance Health from $501.00 to $512.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Baird R W downgraded shares of Elevance Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. Finally, Sanford C. Bernstein reiterated an "outperform" rating on shares of Elevance Health in a report on Friday, March 28th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $514.41.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.